Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 4/20 | 0.35 |
| ▸ | SRC | P12931 | 5/20 | 0.33 |
| ▸ | KDR | P35968 | 4/20 | 0.33 |
| ▸ | ABL1 | P00519 | 3/20 | 0.33 |
| ▸ | ABL2 | P42684 | 3/20 | 0.33 |
| ▸ | TEK | Q02763 | 3/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20182265 | 0.92 | NTRK1 (0.36) | CFTREGFREIF2AK3KDRABL1 | |
| SCHEMBL20182194 | 0.91 | EIF2AK3 (0.36) | CFTREGFREIF2AK3SRCKDR | |
| SCHEMBL20182224 | 0.90 | EGFR (0.39) | CFTREGFRSRCKDRABL1 | |
| SCHEMBL20182271 | 0.89 | CFTR (0.35) | CFTREGFREIF2AK3SRCKDR | |
| SCHEMBL20182191 | 0.89 | ALK (0.34) | CFTREGFREIF2AK3SRCKDR | |
| SCHEMBL20182227 | 0.87 | EGFR (0.36) | EGFREIF2AK3SRCKDRABL1 | |
| SCHEMBL20181906 | 0.87 | EIF2AK3 (0.34) | CFTREGFREIF2AK3SRCKDR | |
| SCHEMBL20182289 | 0.84 | NTRK1 (0.36) | EGFREIF2AK3SRCKDRABL1 | |
| SCHEMBL20182235 | 0.84 | EIF2AK3 (0.34) | EGFREIF2AK3SRCKDRABL1 | |
| SCHEMBL20182198 | 0.84 | SRC (0.34) | CFTREGFREIF2AK3SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |